The purpose of this study is to use a brain imaging method called Pittsburgh B (PIB) Positron Emission Tomography (PET) and Vesicular Cholinergic Transport (VAT) PET to determine dementia subtypes in patients with Parkinson disease (PD). The ultimate goal of this project is to be able to identify individuals with PD who are at risk of developing dementia, and to distinguish the underlying cause of dementia.
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: March 2030
The purpose of this study is to use a brain imaging method called PIB PET and VAT PET to determine dementia subtypes in patients with Parkinson disease (PD). The ultimate goal of this project is to be able to identify individuals with PD who are at risk of developing dementia, and to distinguish the underlying cause of dementia. The investigators will be including both PD and normal subjects in this study. This a long term study and we are considering including a total of 320 participants in this protocol.
- Radiation: PiB and VAT
- There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.
Arms, Groups and Cohorts
- Parkinsons Disease
- Individuals with Parkinsons Disease
- Healthy Controls
- Individuals without Parkinsons Disease
Clinical Trial Outcome Measures
- Investigations of Dementia in Parkinsons Disease
- Time Frame: 2030
- The investigators will perform memory/thinking testing, Lumbar puncture (LP), Magnetic Resonance Imaging (MRI) and (PET) scans to help to determine the cause(s) of memory and thinking in Parkinson Disease. The memory and thinking testing by phone on average at 1.5 years through study completion and then in person on average at 3 years through study completion, this will help monitor if there is any decline in memory and thinking. The Lumbar Puncture is done on willing participants on average at 3 years through study completion to assess for any abnormal proteins and correlate these with any changes in memory and thinking. The MRI is done on average at 3 years through study completion for any abnormal signs or changes in regards to dementia at 3 years. The (PiB) & (VAT) PET scans will be performed on average at 6 years through study completion, which will be analyzed to assess for changes in regards to abnormal proteins and signs of dementia.
Participating in This Clinical Trial
- PD patients must exhibit three of the following cardinal signs: rest tremor, rigidity, bradykinesia, or postural instability; or two of these features with one of the first three displaying asymmetry.
- history of head trauma, major neurological or psychiatric diseases other than Parkinson disease and dementia, e.g. stroke, multiple sclerosis, depression or schizophrenia.
- severe systemic diseases.
- inability to lie still for 90 minutes.
- metallic implants, pacemakers, or any other contraindication to MRI.
- refusal to consent to brain donation.
Gender Eligibility: All
Minimum Age: 50 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- Washington University School of Medicine
- National Institutes of Health (NIH)
- Provider of Information About this Clinical Study
- Overall Official(s)
- Joel S Perlmutter, MD, Principal Investigator, Washington University School of Medicine
- Overall Contact(s)
- Kelly McVey, BSN, 314-362-4154, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.